Skip to main content
SpringerLink
Log in

Intravesikales Gemcitabin für nicht-muskelinvasive Harnblasenkarzinome

Intravesical gemcitabine for non-muscle invasive bladder cancer

  • Evidenzbasierte Medizin
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bohle A, Leyh H, Frei C et al (2009) Single postoperative instillation of gemcitabine in patients with non-muscle invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo controlled phase III multicentre study. Eur Urol 56:495–503

    Article  PubMed  Google Scholar 

  2. Gardmark T, Carringer M, Beckman E et al (2005) Randomised phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder. Urology 66:527–530

    Article  PubMed  Google Scholar 

  3. Addeo R, Caraglia M, Belini S et al (2009) Randomised phase III trial on Gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28:543–558

    Article  PubMed  Google Scholar 

  4. Bendary L, Khalil S, Shahin A et al (2011) Intravesical gemcitabine versus bacillus Calmette-Guerin (BCG) in treatment of non-muscle invasive bladder cancer: short term comparative study. Conference Proceedings American Urological Association 185 (4 Suppl 1):664–665

    Google Scholar 

  5. Porena M, Zingaro M, Lazzeri M et al (2010) Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in highrisk superficial bladder cancer: a randomised prospective study. Urol Int 84:23–27

    Article  CAS  PubMed  Google Scholar 

  6. Lorenzo GD, Perdona S, Damiano R et al (2010) Gemcitabine versus Bacille Calmette-Guerin after initial Bacille Calmette-Guerin failure in non-muscle invasive bladder cancer. Cancer 116:1893–1900

    Article  PubMed  Google Scholar 

  7. Brausi MA, Gontero P, Altieri V et al (2011) Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study. Urol Int 87(4):470–474

    Article  CAS  PubMed  Google Scholar 

  8. Cao M, Ma CK, Ma J et al (2011) Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer. Zhonghua Zhong Liu Za Zhi 33(5):385–387

    CAS  PubMed  Google Scholar 

  9. Gontero P, Oderda M, Mehnert A et al (2013) The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II Trial. Urology 3:857–862

    Article  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. L.-M. Krabbe und S. Schmidt sind Mitglieder von UroEvidence. Es bestehen keine Interessenskonflikte. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Klinik für Urologie, Universitätsklinikum Münster, Albert-Schweitzer Campus 1, GB A1, 48149, Münster, Deutschland

    L.-M. Krabbe

  2. UroEvidence@Deutsche Gesellschaft für Urologie, Kuno-Fischer-Straße 8, 14057, Berlin, Deutschland

    S. Schmidt , PhD, MPH

Authors
  1. L.-M. Krabbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Schmidt , PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to L.-M. Krabbe or S. Schmidt , PhD, MPH.

Additional information

Die Zusammenfassung der Studie ist die Übersetzung des englischen Abstracts der Originalpublikation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krabbe, LM., Schmidt, S. Intravesikales Gemcitabin für nicht-muskelinvasive Harnblasenkarzinome. Urologe 54, 402–405 (2015). https://doi.org/10.1007/s00120-015-3779-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-015-3779-2

Search

Navigation